Inspired by Patients. Driven by Science.
UCB (ucb.com) earns a Brand Analyzer score of 89 out of 100, placing it in the Strong Brand tier among Healthcare brands. Among 3960 Healthcare brands analyzed, UCB ranks in the 98th percentile (category average 73, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 100/100, Digital Presence 100/100, Visual Identity 93/100, Messaging Clarity 95/100, Trust Foundation 97/100, AI Discoverability 65/100, Brand Authority 74/100.
UCB is a global biopharmaceutical company headquartered in the Brussels metropolitan area, founded in 1928. The company focuses on developing therapies for people living with severe neurological and autoimmune conditions. UCB combines scientific research with patient-centered innovation to address areas of significant unmet medical need. Its work involves collaboration with healthcare providers, researchers, and scientific communities to advance treatment options for these severe diseases.
| Brand Name | UCB |
|---|---|
| Domain | ucb.com |
| Industry | Healthcare |
| Founded | 1928 |
| Headquarters | Brussels metropolitan area |
| Main Competitors | Biogen (78/100), Novartis (73/100), Roche (81/100), AbbVie (84/100), Amgen (82/100), Sanofi (82/100), Eli Lilly (78/100) |
Moz Domain Authority 60/100 vs category average 36 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #79,922 on the Tranco list of most-visited sites - strong traffic reinforces the brand's prominence to AI models.
UCB has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "UCB a global biopharmaceutical leader focuses on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions" (Meta description: 22 words (ideal length). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on LinkedIn, Instagram, Facebook, X (Twitter), GitHub; no detected presence on YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
UCB scores 69/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
UCB has a moderate AI-visibility profile at 69/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (75/100) and its weakest is trust (63/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #79,922 (Tranco). The main gaps holding it back: no llms.txt to steer AI to its best pages. In a live check, Claude could already identify UCB from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is UCB?", Claude could identify the brand as of August 2026. UCB is a Belgian biopharmaceutical company focused on neurology and immunology, developing treatments for conditions like epilepsy, Parkinson's disease, and psoriasis. Best known for Biologics and treatments for severe epilepsy and immunology disorders, such as Cimzia and Vimpat.
When asked "Best brands similar to UCB?", Claude would recommend UCB as of August 2026. UCB is a well established global biopharma player with a strong pipeline in neurology and immunology, making it relevant when discussing top pharmaceutical companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
UCB's main competitors include Biogen (78/100), Novartis (73/100), Roche (93/100), AbbVie (84/100), Amgen (82/100). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
UCB and Roche are competitors in Healthcare. Brand Analyzer scores UCB at 89/100 and Roche at 93/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to UCB include Biogen (78/100), Novartis (73/100), Roche (93/100), AbbVie (84/100), Amgen (82/100). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
UCB is a global biopharmaceutical company headquartered in the Brussels metropolitan area, Belgium. It was founded in 1928 and operates within the healthcare sector, specializing in the development of therapies for severe neurological and autoimmune conditions.
Sources: UCB official site
UCB has moderate AI-search visibility, scoring 69/100 on Brand Analyzer's AI visibility composite (visibility 75, trust 63, recommendation 67). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: UCB official site
UCB was founded in 1928. UCB operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
UCB is headquartered in Brussels metropolitan area. UCB operates in the Healthcare category.
Sources: Wikidata
UCB develops biopharmaceutical solutions aimed at improving the lives of people living with severe neurological and autoimmune conditions. The company focuses on scientific research and innovation to create treatments that address significant unmet medical needs in these disease areas, working alongside healthcare providers and research communities.
Sources: UCB official site
UCB scores 67/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: UCB official site
UCB can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: UCB official site
UCB's therapies and services are used by patients living with severe neurological and autoimmune conditions. Additionally, healthcare providers, researchers, and scientific communities involved in treating and studying these diseases engage with UCB's products and research efforts.
Sources: UCB official site
UCB is known for its focus on neurology and immunology, developing biopharmaceutical treatments for severe and often difficult-to-treat conditions. It is recognized as a global biopharmaceutical leader that emphasizes combining scientific expertise with patient-centered innovation to address serious unmet medical needs.
Sources: UCB official site
Ranked closest to UCB: Tietoevry (89/100), The Trevor Project (89/100), Virbac (89/100), Zenoti (89/100).
A step up - brands to learn from: theSkimm (91/100), Oura (91/100).
Category leader: Elsevier (96/100).